ENCLAI Daily · Article of the day 03 Oct 2026 · ENCLAI Editorial

2026 pediatric cancer guideline maintains levofloxacin and antifungal prophylaxis recommendations

GuidelineJournal of clinical oncology · 2 Oct 2026 · PubMed 42826360
Statement

Future research should refine prophylaxis indications for different patient subgroups.

Strength of recommendation“The panel maintained a conditional recommendation to consider antibacterial prophylaxis in pediatric patients with AML and relapsed ALL and a strong recommendation to use levofloxacin when antibacterial prophylaxis is planned.”
Statements are quoted word for word from the published abstract; the labels come from each statement’s own wording (“is recommended”, “should”, “may be preferred”, “should not”). Read the full guidance before applying it.
Customise it in Visual Studio
Infographic — study at a glance
What the authors report
Evidence and source
Infographic — study at a glance

The publication

The 2026 Pediatric Oncology Group of Ontario clinical practice guideline maintains strong recommendations for levofloxacin and antifungal prophylaxis in specific pediatric cancer and transplant patients. The update incorporates 13 new randomized trials published since 2019 into a total evidence base of 195 trials.

Who the findings apply to

The guideline applies to pediatric patients with cancer and hematopoietic cell transplantation recipients.

Specific recommendations address pediatric patients with acute myeloid leukemia and relapsed acute lymphoblastic leukemia for antibacterial prophylaxis.

Antifungal prophylaxis recommendations apply to pediatric patients with acute myeloid leukemia and allogeneic hematopoietic cell transplantation recipients.

Why this matters

The guideline harmonizes procedures and recommendations across antibacterial and antifungal prophylaxis for pediatric patients with cancer and hematopoietic cell transplantation recipients. By updating systematic reviews of randomized clinical trials using the Grading of Recommendations Assessment, Development and Evaluation approach, the panel ensures recommendations reflect the most current evidence for infection prevention in these vulnerable populations.

What the study found

The panel maintained a conditional recommendation to consider antibacterial prophylaxis in pediatric patients with acute myeloid leukemia and relapsed acute lymphoblastic leukemia.

A strong recommendation to use levofloxacin when antibacterial prophylaxis is planned was maintained.

A new conditional recommendation was introduced to consider using no antibacterial prophylaxis in patients unable to receive levofloxacin.

Strong recommendations to use antifungal prophylaxis in pediatric patients with acute myeloid leukemia and allogeneic hematopoietic cell transplantation recipients were maintained.

A strong recommendation to use an echinocandin or a mold-active azole when antifungal prophylaxis is planned was maintained.

Three new good practice statements were added, focusing on drug interactions, infection prevention practices, and monitoring infection epidemiology.

What the result does not establish

The update identified 13 new randomized trials published since 2019, resulting in 195 total trials evaluated.

The authors conclude that future research should refine prophylaxis indications for different patient subgroups.

Authors’ conclusion

“This update consolidates and harmonizes CPGs for systemic antibacterial and antifungal prophylaxis in pediatric patients with cancer and HCT patients. Future research should refine prophylaxis indications for different patient subgroups.”

Study and sources

Clinical Practice Guideline for Systemic Antibacterial and Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Cell Transplant Recipients: 2026 Update

Guidelines & recommendations · Journal of clinical oncology · 2026-10-02

Sources and limitations

Share this briefing
ENCLAI tracks outbreaks like this live, from official sources worldwide. Start 7-day free trial  ·  Request a demo →

Follow ENCLAI News

Get new briefings in your news reader. No ENCLAI account needed.

The daily disease brief

One email a day: what changed in official disease reporting worldwide, with the source named for every number. Reported facts only — no forecasts and no interpretation.

Double opt-in — we send a confirmation link and nothing else until you click it. One-click unsubscribe on every email. See our privacy notice.